Skip to contentShah Rajeev M. — Black Diamond Therapeutics, Inc. insider: 215 transactions · InsiderLensShah Rajeev M.
- Former 10% owners and Director at DICE Therapeutics, Inc. · on record since Aug 9, 2023
- Director at Acrivon Therapeutics, Inc. · on record since Apr 23, 2026
- 10% owner at Acrivon Therapeutics, Inc. · on record since Apr 23, 2026
- 10% owner at ARS Pharmaceuticals, Inc. · on record since Mar 27, 2024
- 10% owner at BOLD ENERGY INC. · on record since Mar 27, 2024
- Director at Cidara Therapeutics, Inc. · on record since Apr 30, 2024
- Former 10% Owner at iTeos Therapeutics, Inc. · on record since May 14, 2024
- Director at Septerna, Inc. · on record since Oct 30, 2024
- 10% owner at Septerna, Inc. · on record since Oct 30, 2024
- 10% owner at 4D Molecular Therapeutics, Inc. · on record since Nov 25, 2024
- Director at Sionna Therapeutics, Inc. · on record since Feb 10, 2025
- 10% owner at Sionna Therapeutics, Inc. · on record since Feb 10, 2025
- 10% owner at Cidara Therapeutics, Inc. · on record since Jun 30, 2025
- 10% owner at Prelude Therapeutics Inc · on record since Apr 28, 2026
- Director at Evommune, Inc. · on record since Nov 5, 2025
- 10% owner at Evommune, Inc. · on record since Nov 5, 2025
- Director at SCHERING PLOUGH CORP · on record since Feb 11, 2026
- 10% owner at SCHERING PLOUGH CORP · on record since Feb 11, 2026
- Director at Vor Biopharma Inc. · on record since Apr 6, 2026
- 10% owner at Vor Biopharma Inc. · on record since Apr 6, 2026
- 10% owner at ACETO CORP · on record since Apr 13, 2026
- Director at Ra Pharmaceuticals, Inc. · on record since Oct 31, 2016
- Director at Climb Bio, Inc. · on record since Apr 29, 2026
- 10% owner at Climb Bio, Inc. · on record since Apr 29, 2026
- Director at Hemab Therapeutics Holdings, Inc. · on record since Apr 30, 2026
- 10% owner at Hemab Therapeutics Holdings, Inc. · on record since Apr 30, 2026
- 10% owner at Werewolf Therapeutics, Inc. · on record since May 12, 2026
- Director at Artiva Biotherapeutics, Inc. · on record since May 13, 2026
- 10% owner at Artiva Biotherapeutics, Inc. · on record since May 13, 2026
- Director at KalVista Pharmaceuticals, Inc. · on record since Nov 23, 2016
- Director at Tyra Biosciences, Inc. · on record since Jun 1, 2026
- 10% owner at Tyra Biosciences, Inc. · on record since Jun 1, 2026
- Director at ARBIOS SYSTEMS INC · on record since Jun 5, 2026
- 10% owner at ARBIOS SYSTEMS INC · on record since Jun 5, 2026
- Director at Parabilis Medicines, Inc. · on record since Jun 9, 2026
- Director at Bicara Therapeutics Inc. · on record since Jun 10, 2026
- 10% owner at Bicara Therapeutics Inc. · on record since Jun 10, 2026
- Director at Nkarta, Inc. · on record since Jun 11, 2026
- 10% owner at Nkarta, Inc. · on record since Jun 11, 2026
- Director at Janux Therapeutics, Inc. · on record since Jun 12, 2026
- 10% owner at Janux Therapeutics, Inc. · on record since Jun 12, 2026
- 10% owner at Parabilis Medicines, Inc. · on record since Jun 15, 2026
- Director at LENZ Therapeutics, Inc. · on record since Jun 15, 2026
- 10% owner at LENZ Therapeutics, Inc. · on record since Jun 15, 2026
- Director at Kala Pharmaceuticals, Inc. · on record since Jul 26, 2017
- 10% owner at Kala Pharmaceuticals, Inc. · on record since Jul 21, 2017
- 10% owner at KalVista Pharmaceuticals, Inc. · on record since Oct 16, 2017
- Director at Solid Biosciences Inc. · on record since Jan 30, 2018
- 10% owner at Wave Life Sciences Ltd. · on record since Apr 5, 2021
- 10% owner at Ra Pharmaceuticals, Inc. · on record since Feb 16, 2018
- Director at Eidos Therapeutics, Inc. · on record since Jun 22, 2018
- Director at STERLING FINANCIAL CORP /WA/ · on record since Sep 17, 2019
- 10% owner at STERLING FINANCIAL CORP /WA/ · on record since Sep 17, 2019
- Director at 89bio, Inc. · on record since Nov 13, 2019
- 10% owner at 89bio, Inc. · on record since Nov 13, 2019
- 10% owner at Phathom Pharmaceuticals, Inc. · on record since Nov 4, 2019
- Director at Black Diamond Therapeutics, Inc. · on record since Jan 29, 2020
- 10% owner at THORATEC CORP · on record since Jan 24, 2020
- 10% owner at scPharmaceuticals Inc. · on record since Feb 21, 2020
- 10% owner at 11 GOOD ENERGY INC · on record since Mar 17, 2020
- 10% owner at Verastem, Inc. · on record since Mar 5, 2020
- 10% owner at RHYTHM PHARMACEUTICALS, INC. · on record since Jun 29, 2020
- 10% owner at Akouos, Inc. · on record since Jun 25, 2020
- 10% owner at Forma Therapeutics Holdings, Inc., · on record since Jun 24, 2020
- 10% owner at Vaxcyte, Inc. · on record since Jun 18, 2020
- 10% owner at MANHATTAN PHARMACEUTICALS INC · on record since May 7, 2020
- 10% owner at PMV Pharmaceuticals, Inc. · on record since Sep 29, 2020
- 10% owner at iTeos Therapeutics, Inc. · on record since Jul 29, 2020
- 10% owner at Inozyme Pharma, Inc. · on record since Jul 28, 2020
- 10% owner at Inhibrx Biosciences, Inc. · on record since Aug 24, 2020
- 10% owner at DYNEGY INC /IL/ · on record since Sep 23, 2020
- 10% owner at Pandion Therapeutics, Inc. · on record since Jul 22, 2020
- Director at Cytek Biosciences, Inc. · on record since Jul 29, 2021
- 10% owner at MED GEN INC · on record since Dec 17, 2020
- 10% owner at Solid Biosciences Inc. · on record since Dec 14, 2020
- 10% owner at Protalix BioTherapeutics, Inc. · on record since Nov 6, 2020
- Former 10% Owner at RHYTHM PHARMACEUTICALS, INC. · on record since Dec 4, 2020
- 10% owner at XENOMICS INC · on record since Oct 2, 2020
- 10% owner at Iterum Therapeutics plc · on record since Dec 2, 2020
- Director at Protalix BioTherapeutics, Inc. · on record since Feb 11, 2021
- Director at Therapeutics Acquisition Corp. · on record since Jun 30, 2021
- Director at Jade Biosciences, Inc. · on record since Jun 29, 2021
- 10% owner at Jade Biosciences, Inc. · on record since Jun 29, 2021
- Director at Werewolf Therapeutics, Inc. · on record since Apr 29, 2021
- Director at Icosavax, Inc. · on record since Jul 28, 2021
- 10% owner at Icosavax, Inc. · on record since Jul 28, 2021
- Director at DICE Therapeutics, Inc. · on record since Sep 20, 2021
- 10% owner at DICE Therapeutics, Inc. · on record since Sep 20, 2021
- Director at Wave Life Sciences Ltd. · on record since Aug 18, 2021
- 10% owner at RxSight, Inc. · on record since Aug 13, 2021
- 10% owner at AcuNetx, Inc. · on record since Mar 31, 2022
- 10% owner at Cytek Biosciences, Inc. · on record since Mar 16, 2022
- Director at PepGen Inc. · on record since May 12, 2022
- 10% owner at PepGen Inc. · on record since May 12, 2022
- Director at iTeos Therapeutics, Inc. · on record since Jun 10, 2022
- Director at Forma Therapeutics Holdings, Inc., · on record since Jun 9, 2022
- 10% owner at Fulcrum Therapeutics, Inc. · on record since Aug 26, 2022
- Director at ARS Pharmaceuticals, Inc. · on record since Nov 10, 2022
- Former 10% owner at 11 GOOD ENERGY INC · on record since Feb 27, 2023
- Director at Mineralys Therapeutics, Inc. · on record since Feb 16, 2023
- 10% owner at Mineralys Therapeutics, Inc. · on record since Feb 13, 2023
Insider trading activity of Shah Rajeev M.
- Transactions on record
- 215
- since Oct 31, 2016
- Open-market buys
- 52
- $654.2M
- Open-market sells
- 28
- $46.4M
- Companies traded
- 31
- last filing Mar 31, 2026
Figures computed from official regulatory filings — methodology.
Companies where Shah Rajeev M. has traded
- Mineralys Therapeutics, Inc.2 tx · $8.8M · Mar 31, 2026
- ARBIOS SYSTEMS INC9 tx · $50M · Mar 18, 2026
- SCHERING PLOUGH CORP1 tx · Feb 9, 2026
- 89bio, Inc.13 tx · $42.5M · Nov 3, 2025
- Vor Biopharma Inc.18 tx · $63.7M · Oct 17, 2025
- Cidara Therapeutics, Inc.1 tx · Jan 7, 2025
- Septerna, Inc.6 tx · $75.1M · Oct 30, 2024
- Fulcrum Therapeutics, Inc.2 tx · Aug 23, 2024
- Jade Biosciences, Inc.9 tx · $40.5M · Jun 20, 2024
Track record of Shah Rajeev M.
Statistical track record
Free- Open-market buys
- 53
- Last buy
- Mar 30, 2026
Win rates and median returns are available with a free account (5 insiders/month).
Create a free account→Transaction history of Shah Rajeev M.
Co-insiders of Shah Rajeev M.
- Kolchinsky Peter4D Molecular Therapeutics, Inc. +24
- RA Capital Biotech Fund LP4D Molecular Therapeutics, Inc. +24
- RA CAPITAL MANAGEMENT, LLC4D Molecular Therapeutics, Inc. +24
- RA Capital Nexus Fund II, L.P.Acrivon Therapeutics, Inc. +9
- RA Capital Nexus Fund III, L.P.Artiva Biotherapeutics, Inc. +7
- ORBIMED ADVISORS LLCACETO CORP +5
- RA Capital Nexus Fund, L.P.Artiva Biotherapeutics, Inc. +5
This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →
2 tx · $61.4M · Feb 8, 2024
| Company | Filed | Type | Qty | Price | Value · USD | Src |
|---|
| Mar 31, 2026 | Buy | 310,700 | 23.67 USD | $7.4M | SEC |
| Mar 31, 2026 | Buy | 58,300 | 24.16 USD | $1.4M | SEC |
| Mar 18, 2026 | Award | 6,060,606 | 3.30 USD | $20M | SEC |
| Feb 9, 2026 | AwardD | 27,400 | 0.00 USD | $0 | SEC |
| Nov 3, 2025 | Other | -335,364 | — | — | SEC |
| Nov 3, 2025 | OtherD | -12,500 | 0.00 USD | $0 | SEC |
| Nov 3, 2025 | OtherD | -45,150 | 0.00 USD | $0 | SEC |
| Nov 3, 2025 | OtherD | -56,400 | 0.00 USD | $0 | SEC |
| Nov 3, 2025 | Other | -19,554,319 | — | — | SEC |
| Nov 3, 2025 | OtherD | -7,000 | 0.00 USD | $0 | SEC |
| Nov 3, 2025 | OtherD | -27,400 | 0.00 USD | $0 | SEC |
| Nov 3, 2025 | OtherD | -4,331,081 | 0.00 USD | $0 | SEC |
| Nov 3, 2025 | OtherD | -25,000 | 0.00 USD | $0 | SEC |
| Nov 3, 2025 | OtherD | -7,000 | 0.00 USD | $0 | SEC |
| Oct 17, 2025 | Sell | -21,804 | 29.32 USD | $639.3K | SEC |
| Oct 17, 2025 | Sell | -20 | 31.35 USD | $627 | SEC |
| Oct 17, 2025 | Sell | -3,108 | 30.36 USD | $94.4K | SEC |
| Oct 17, 2025 | Sell | -174,594 | 29.12 USD | $5.1M | SEC |
| Oct 17, 2025 | Sell | -2,492 | 31.00 USD | $77.3K | SEC |
| Oct 17, 2025 | Sell | -8,384 | 30.55 USD | $256.1K | SEC |
| Oct 17, 2025 | Sell | -42,699 | 30.55 USD | $1.3M | SEC |
| Oct 17, 2025 | Sell | -30,758 | 30.28 USD | $931.4K | SEC |
| Oct 17, 2025 | Sell | -6,040 | 30.28 USD | $182.9K | SEC |
| Oct 17, 2025 | Sell | -34,284 | 29.12 USD | $998.4K | SEC |
| Oct 17, 2025 | Sell | -12,691 | 31.00 USD | $393.4K | SEC |